In This Section

CICR Conferences and Meetings

UpComing Conferences and meetings


October 11-15, 2023
Hynes Convention Center
Boston, Massachusetts

Conference Cochairs

Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands (EORTC)

AACR-CICR Town Hall Meeting and Networking Session
Friday, October 13, 2023
6:00 pm-7:30 pm ET
Level 3, Room 312

Theme: Approaches to Targeting the Guardian of the Genome, p53

Chair and Moderator:
Lori Friedman, PhD
ORIC Pharmaceuticals, San Francisco, California
CICR Working Group Chair-Elect

Leila Alland, MD
PMV Pharmaceuticals, Cranbury, New Jersey
Discovery and Development of PC14586, a first-in-class small molecule reactivator of p53 Y220C

Charles Johannes, PhD 
Consultant, Boston, Massachusetts
Design-Rules for Stapled Peptides with in vivo Activity and their Application to Mdm2/X antagonistsS Modulation

Md Kabir, PhD
Icahn School of Medicine at Mount Sinai, New York, New York
AceTAC, A Novel, Innovative and Targeted Protein Acetylation Modality

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2023 Molecular Targets and Cancer Therapeutics conference will return to the Hynes Convention Center in Boston. This program attracts 1,200-1,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach to exchange information early in the development process.
Learn more.